Mark Breidenbach
Stock Analyst at Oppenheimer
(2.32)
# 1,049
Out of 4,641 analysts
63
Total ratings
37.1%
Success rate
2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $24.78 | +21.07% | 4 | Sep 4, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $14 → $13 | $2.77 | +369.31% | 5 | May 21, 2024 | |
| EPIX ESSA Pharma | Reiterates: Outperform | $17 | $5.37 | +216.57% | 5 | Dec 13, 2023 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $26.52 | +258.22% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $2.16 | +1,057.41% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $1.57 | +536.94% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $12 | $0.76 | +1,485.20% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $4 | $0.42 | +844.06% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $1.69 | +314.20% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $1.92 | +1,566.67% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $13 | $2.25 | +477.78% | 3 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $15 | $9.82 | +52.75% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $120 | $1.39 | +8,533.09% | 4 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $1.00 | +2,200.23% | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $225 → $195 | $0.30 | +64,277.68% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $135 | $0.51 | +26,231.19% | 3 | Dec 13, 2019 |
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $24.78
Upside: +21.07%
Allogene Therapeutics
May 21, 2024
Maintains: Outperform
Price Target: $14 → $13
Current: $2.77
Upside: +369.31%
ESSA Pharma
Dec 13, 2023
Reiterates: Outperform
Price Target: $17
Current: $5.37
Upside: +216.57%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $26.52
Upside: +258.22%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $2.16
Upside: +1,057.41%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $1.57
Upside: +536.94%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $12
Current: $0.76
Upside: +1,485.20%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $4
Current: $0.42
Upside: +844.06%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $1.69
Upside: +314.20%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $1.92
Upside: +1,566.67%
Mar 3, 2023
Maintains: Outperform
Price Target: $15 → $13
Current: $2.25
Upside: +477.78%
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $9.82
Upside: +52.75%
Oct 18, 2022
Maintains: Outperform
Price Target: $90 → $120
Current: $1.39
Upside: +8,533.09%
Apr 26, 2021
Initiates: Outperform
Price Target: $23
Current: $1.00
Upside: +2,200.23%
May 12, 2020
Maintains: Outperform
Price Target: $225 → $195
Current: $0.30
Upside: +64,277.68%
Dec 13, 2019
Upgrades: Outperform
Price Target: $135
Current: $0.51
Upside: +26,231.19%